Sick by Design: How Big Pharma's Fossil Fuel Investments Are Quietly Killing the Research That Could Save Us

Let's start with a number: $4.2 billion. That's a rough estimate of how much Americans spend every year managing asthma — a disease with a well-documented connection to air pollution from fossil fuel combustion. Now ask yourself: who profits from that spending? And who profits from the pollution causing it in the first place?

The answer, in a disturbing number of cases, is the same company.

Some of the largest pharmaceutical corporations in the United States — household names whose logos appear on hospital walls and TV commercials urging you to "ask your doctor" — are also significant investors in the fossil fuel sector. Through endowments, pension funds, asset management arms, and direct equity holdings, Big Pharma has quietly built a financial stake in the very industries science has linked to the chronic diseases these companies are supposedly racing to cure.

And according to researchers, public health advocates, and former industry insiders, that conflict of interest isn't just ethically ugly. It's actively shaping what science gets funded, published, and acted upon.

Follow the Endowment

The mechanism isn't always obvious, and that's part of the problem. Most major pharmaceutical companies don't just make drugs — they manage enormous pools of capital. Their research foundations, charitable arms, and institutional investment portfolios are often invested in diversified funds that include energy sector stocks, including oil, gas, and petrochemical companies.

When a pharmaceutical foundation funds a university research chair, it typically comes with strings — explicit or implicit — about what kinds of research get prioritized. Studies examining the link between fossil fuel pollution and respiratory illness, pediatric asthma rates in refinery communities, or cancer clusters near petrochemical plants represent a direct threat to that investment portfolio.

Several academic researchers spoken to for this piece — all of whom requested anonymity for fear of losing funding — described a consistent pattern: grant applications that touch on environmental causes of disease face longer review cycles, higher rejection rates, and more demands for revision than comparable studies examining genetic or lifestyle factors. One epidemiologist at a Midwestern university described submitting a proposal to study asthma hospitalization rates in zip codes with high industrial air pollution. "The feedback I got wasn't scientific," she said. "It was about framing. They kept asking me to broaden the scope, dilute the environmental angle. Eventually I just shelved it."

The Double Dip

Here's the part that should make your blood boil. The business logic, once you see it, is almost elegant in its cruelty.

Fossil fuel combustion — from power plants, refineries, diesel trucks, and gas-powered vehicles — releases particulate matter, nitrogen dioxide, ozone, and dozens of other compounds that damage human lungs and cardiovascular systems. The communities hit hardest are low-income neighborhoods and communities of color, which are disproportionately located near industrial facilities. These communities also tend to have less access to healthcare, meaning the diseases fester longer and cost more to treat.

Now: who sells the inhalers, the corticosteroids, the blood pressure medications, the chemotherapy regimens? Who benefits financially when chronic disease rates climb?

If a pharmaceutical company simultaneously holds equity in ExxonMobil and sells the drugs used to manage pollution-related illness, suppressing research that might accelerate a shift away from fossil fuels isn't just ideologically convenient. It's financially rational. The sicker the air, the sicker the population. The sicker the population, the stronger the revenue stream.

This isn't a conspiracy theory. It's a structural incentive built into the way American capital works — and almost nobody is talking about it.

What the Research Actually Shows (When It Gets Through)

The studies that do make it into peer-reviewed journals are damning enough. Research published in environmental health journals has repeatedly confirmed that children living near oil refineries and petrochemical plants face significantly elevated rates of asthma, leukemia, and developmental disorders. Adults in these communities show higher rates of chronic obstructive pulmonary disease, cardiovascular disease, and certain cancers.

A landmark 2021 analysis in The Lancet estimated that pollution from fossil fuel combustion is responsible for approximately one in five deaths globally — roughly 8 million people per year. In the United States, the health costs of air pollution from fossil fuels have been estimated at over $800 billion annually, when you factor in healthcare expenditures, lost productivity, and premature death.

Those numbers represent human suffering on a scale that's almost incomprehensible. They also represent an enormous market for pharmaceutical products.

The research that doesn't make it through — the studies killed in committee, the grant proposals quietly rejected, the clinical trials that never get funded — is harder to document precisely because it doesn't exist on paper. But the pattern of what's missing is visible to anyone who looks. Environmental causation research is chronically underfunded relative to genetic and pharmaceutical intervention research. The gap isn't accidental.

The Regulatory Gap Nobody Wants to Close

You might expect the FDA, the NIH, or Congress to have something to say about all this. You'd be disappointed.

The NIH, which distributes tens of billions in research funding annually, does not require grant applicants or their institutions to disclose fossil fuel investment holdings as a potential conflict of interest. Pharmaceutical companies are required to disclose financial conflicts in clinical trial research — but environmental epidemiology, the field most likely to expose pollution-disease links, operates under a patchwork of disclosure rules that vary by journal and institution.

Meanwhile, the pharmaceutical lobby — one of the most powerful in Washington — has shown zero interest in pushing for tighter conflict-of-interest rules in environmental health research. Funny, that.

Several public health advocacy groups have called for mandatory disclosure of fossil fuel investment holdings by any institution receiving federal research dollars. The proposal has gone nowhere. Industry-friendly members of Congress have made sure of that.

Communities Left to Connect the Dots

In places like Cancer Alley in Louisiana, the Houston Ship Channel corridor in Texas, and the refinery-ringed neighborhoods of Richmond, California, residents don't need a peer-reviewed study to tell them something is wrong. They can see it in their kids' nebulizer schedules. They can count the funerals.

What they can't do — at least not yet — is force a reckoning with an industry that profits from their illness while choking the research pipelines that might lead to accountability.

That's the real scandal here. It's not just that pharmaceutical companies invest in fossil fuels. It's that those investments are quietly distorting the scientific record, delaying the kind of research that could accelerate the energy transition, and keeping entire communities trapped in a cycle of pollution and chronic disease.

What Needs to Happen

This isn't unsolvable. A few concrete steps would go a long way.

First, the NIH and all federal research funding bodies should require full disclosure of fossil fuel investment holdings — by institutions, foundations, and individual researchers — as a condition of receiving public money. If your endowment profits from Chevron, the public deserves to know that before you publish research on air quality.

Second, Congress should hold hearings — real ones, not performance theater — on the conflict of interest between pharmaceutical investment portfolios and environmental health research funding. Subpoena the documents. Follow the money.

Third, universities and academic medical centers need to divest their endowments from fossil fuels. Full stop. You cannot credibly claim to be in the business of human health while your investment portfolio is funding the industry causing the most preventable disease burden on the planet.

The communities living in the shadow of refineries and petrochemical plants have been waiting for science to catch up with what they already know. The least we can do is stop letting the people profiting from their suffering decide which questions get asked.

Free The Planet is an independent publication. We don't take money from pharmaceutical companies, fossil fuel interests, or anyone else with a stake in keeping you in the dark. If this story matters to you, share it.